Information Provided By:
Fly News Breaks for February 21, 2017
AMPH
Feb 21, 2017 | 09:52 EDT
Wells Fargo analyst David Maris said the fact that the FDA issued a Complete Response Letter, or CRL, to Amphastar on its nasal naloxone product was both "disappointing and surprising" given that the company currently markets the leading injectable generic naloxone. However, the stock's decline in pre-market trading "seems to more than reflect the nasal naloxone opportunity," added Maris, who keeps an Outperform rating on Amphastar shares, which are down 15% in early trading after the opening bell to $15.62.
News For AMPH From the Last 2 Days
There are no results for your query AMPH